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Abstract
The current world epidemic of type 2 diabetes mellitus results from two general groups of causative factors. One is the influence of strong
pathogenetic environmental pressures — also described as negative civilizational influence — on the very large subpopulation, assessed at
30% of the total world population, which is genetically predisposed to react to this external stress with the symptoms of type 2 diabetes
mellitus. Such a pathogenetic reaction is based on the appearance of cellular and organ resistance to insulin. A second factor involves the
beta cells of the pancreatic islets and their dysfunction.
For these reasons, studies on the aetiology of insulin resistance have significance, both theoretical and practical. There are many biological
deviations that can produce cellular insulin resistance and underutilization of glucose. The mechanism that is always present is the de-
crease of cellular glucose transport. For this reason, it should be approached as a potential target for preventive and therapeutic actions.
These pathophysiological and clinical circumstances were the motivation for presenting a review of cellular glucose transport pathophys-
iology, which contributes to the aetiology of insulin resistance, cellular underutilization of glucose, and type 2 diabetes mellitus. They
underline the significance of cellular glucose transport as a target for prevention and therapy of type 2 diabetes mellitus and other insulin-
resistant conditions.
This review presents comments about the influence on cellular glucose transport of diet, physical exercise, and pharmacotherapeutic
agents, based on the authors’ studies. The review could contribute to an innovative approach to the pathogenesis, prevention, and thera-
py of type 2 diabetes mellitus and other conditions related to insulin resistance. (Pol J Endocrinol 2010; 61 (3): 292–302)
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Streszczenie
Epidemia cukrzycy typu 2 na świecie wynika z dwóch głównych grup czynników przyczynowych. Jedną z nich jest wpływ czynników
środowiskowych, opisywany również jako negatywny wpływ cywilizacji. Szacuje się, że około 30% całkowitej populacji na świecie ma
genetyczną predyspozycję do ujawnienia objawów cukrzycy typu 2 pod wpływem czynników zewnętrznych. Zjawisko to jest związane
z komórkową i narządową opornością na insulinę. Druga grupa czynników jest związana z dysfunkcją komórek b trzustki.
W związku z powyższym badania etiologii insulinooporności mają znaczenie zarówno teoretyczne, jak i praktyczne. Mechanizmem,
który prowadzi do wielu zaburzeń metabolicznych, a przede wszystkim do insulinooporności jest spadek dokomórkowego transportu
glukozy. Z tego powodu dokomórkowy transport glukozy powinien być uważany jako potencjalny cel postępowania prewencyjnego
i terapeutycznego.
W opracowaniu przedstawiono postępy badań nad dokomórkowym transportem glukozy w aspekcie patofizjologii insulinooporności
i cukrzycy typu 2. Najnowsze doniesienia naukowe podkreślają kluczową rolę dokomórkowego transportu glukozy jako celu prewencji
i terapii cukrzycy typu 2. W artykule opisano obecny stan wiedzy na temat wpływu diety, wysiłku fizycznego oraz terapii farmakologicz-
nej na dokomórkowy transport glukozy. (Endokrynol Pol 2010; 61 (3): 292–302)
Słowa kluczowe: insulinooporność, dokomórkowy transport glukozy, cukrzyca typu 2 — patogeneza i terapia
Introduction
A bilayer lipid cell membrane is impermeable to
monosaccharides, and therefore glucose needs a bio-
logical transport system consisting of specialized trans-
port proteins. Those proteins provide physiological
harmony of glucose cell supply and its further metabo-
lism.
Cellular glucose metabolism is a complex, multistage
process. Individual process stages are coordinated by
specialized regulatory systems. In physiological condi-
tions, a quantitative coordination exists between the
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activity of the molecular intracellular glucose transport
system (CGT) and intermediate glucose plasma metab-
olism. Insulin belongs to the most important regulators
of this relationship [1–3].
In diabetes mellitus, this coordination becomes im-
paired. Tissue glucose utilization is diminished despite
the existence of hyperglycaemia. The primary reason
for this impairment is the coexistence of insulin defi-
ciency and insulin resistance [4, 5]. Both of these patho-
genic disturbances cause a shortage of insulin regulato-
ry action on the cells and decrease cellular glucose trans-
port and the utilization of glucose. This always involves
abnormalities in the insulin signalling pathway [6–10].
Insulin resistance — the role in the
aetiology of clinical syndromes
The physiological relationship between glycaemia and
serum insulin concentration has the character of a lin-
ear variable. The level and the course of the relation-
ship between glycaemia and cellular glucose utilization
is individually different but is kept within a relatively
narrow physiological range in healthy persons. The
dependence between glycaemia and insulinaemia,
when shifted towards higher levels, is diagnostic for
insulin resistance [11, 12].
The list of the clinical syndromes and disturbances
with insulin resistant hyperglycaemia is long [13].
Examples are listed below:
— obesity, particularly visceral, disturbances in adi-
ponectin and other cytokines secretion by adipo-
cytes;
— hyperglycaemia coexisting with hyperinsulinaemia
in type 2 diabetes mellitus;
— dyslipidaemia, mostly mixed with the elevation of
“small dense” LDL of triglycerides and the decrease
of HDL, non-alcoholic fatty liver;
— arterial hypertension, particularly associated with
obesity;
— hypercoagulability with PAI-I and fibrinogen eleva-
tion;
— atherogenic disturbances in endothelial cell function;
— microalbuminuria;
— polycystic ovary syndrome;
— states with an increase of CRP and of low-grade in-
flammatory markers.
All of above clinical conditions constitute an indica-
tion for diagnostic tests permitting a quantitative assess-
ment of insulin resistance using metabolic clamp or
mathematical methods of assessing the resistance to
insulin in an indirect way.
A diagnosis of insulin resistance consequently means
an indication for therapy including modification of lif-
estyle and the use of insulin sensitizers such as bigu-
anides, tiazolidinediones, acarbose, incretins, or incre-
tin enhancers [14, 15].
Cellular glucose transport and insulin
signalling pathway — new areas of
aetiological research in diabetes mellitus
The medical practitioner is mainly interested in the
achievements of the basic biological sciences that lead
to a better understanding of the disease and create more
efficient methods of diagnosis, prevention, and thera-
py. The elucidation of biochemical and molecular mech-
anisms of insulin resistance may lead to more effective
practice. Due to epidemiological pressures, this is also
the task of primary care physicians.
Insulin resistance can be caused by structural or
functional changes in any of the insulin regulatory ac-
tions on intracellular signalling mediator molecules,
from the insulin receptor to the genes [17]. The defect
of glucose utilization may therefore be induced in any
phase of the signalling process: from the binding of in-
sulin to its receptor, through the activity of GLUT trans-
porters and of proteins responsible for the transloca-
tion of these transporters to the cellular membrane, to
the structural or functional abnormalities of other sig-
nalling molecules, and transcriptional factors on the
route of the insulin signal to genes.
Disorders at the level of insulin receptor have been
thoroughly examined, especially the mutations disturb-
ing its function as a tyrosine phosphatase. The effects
of such mutations can be seen in special forms of type 2
diabetes mellitus that are accompanied by this type of
insulin resistance.
The utilization of glucose by the muscles and adi-
pose tissue can be impaired by many other disturbanc-
es in the signalling processes. In patients with type 2
diabetes, different abnormalities concerning the signal
transduction cascade below the insulin receptor have
already been found. For example, in patients with in-
sulin resistance (not necessarily with type 2 diabetes),
impaired IRS 1 phosphorylation and impaired PI-3 ki-
nase activation in skeletal muscles are frequently en-
countered [18, 19]. In the adipose tissue of patients with
type 2 diabetes mellitus and obesity, a decrease in glu-
cose transport is connected with changes in the expres-
sion of the GLUT4 protein. In such patients, up to
80–90% of GLUT4 function in adipocytes could be lost.
These phenomena result from impaired insulin sensi-
tivity in the peripheral tissues, mainly in striated mus-
cles, which are responsible for 70–80% of insulin-stim-
ulated glucose utilization, and in adipose tissue, which
is responsible for 5–20% of the insulin resistant glucose
underutilization. It should be emphasized that cellular
glucose metabolic underutilization is always connect-
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ed with impairment of cellular glucose transport. In this
way, a decrease of the glucose transport contributes to
hyperglycaemia.
The “transport” hyperglycaemia in diabetes mellitus
may arise in two ways: 1) as a result of a decrease in the
GLUT transporters’ expression and concentration, or 2)
as an effect of functional disturbances in the process of
the GLUT transporters’ intercellular translocation.
Studies of the impairment of cellular glucose trans-
port in diabetes mellitus, particularly in type 2, should
now be seen as a new potential sphere of clinical activ-
ity (Table I) [6–9].
In abdominal obesity — after normal body mass is
restored the insulin receptor regains its lost tyrosine
phosphatase activity. Disorders of the expression and
translocation of glucose transporter GLUT4 could be
normalized and insulin sensitivity restored.
GLUT4 expression and pre-diabetic state
Insulin resistance is more frequent in the offspring of
diabetic parents. This is shown in Figure 1.
In our own studies, GLUT4 protein expression was
observed in peripheral blood lymphocytes in subjects
with pre-diabetes. The aim of the study was to com-
pare GLUT4 quantitative expression in lymphocytes in
a type 2 diabetes mellitus risk group pre-diabetes with
healthy subjects. The study groups included 1) 15 pre-
diabetic subjects and 2) 15 persons with normal glucose
tolerance and a positive family history of type 2 diabe-
tes mellitus (first-degree relatives). As a control group,
15 healthy persons with no family history of diabetes
mellitus were enrolled.
The lymphocytes demonstrating expression of
GLUT4 were labelled with the use of indirect immunof-
luorescence. The quantitative determination of GLUT4
was performed by flow cytometry. In the control group,
GLUT4 expression was on the level of 12% ± 1.5% and
was significantly lower when compared with both pre-
diabetic subjects (18.2% ± 8.8%) and the positive fami-
ly history group (17.9% ± 9%). GLUT4 overexpression
in subjects with a positive family history of type 2 dia-
betes mellitus suggests cellular glucose transport dis-
turbances prior to hyperglycaemia (20). Determination
of GLUT4 expression, therefore, appears to be a possi-
bly useful method of early detection in individuals at
high risk of diabetes mellitus type 2.
Cellular glucose transport as a therapeutic
target in type 2 diabetes mellitus
Diet and the function of GLUT4
It has been observed that insulin resistance caused by
a high-fat, high-sugar diet is the result of a direct de-
crease of the ability of insulin to activate GLUT4 in
muscles. GLUT4 overexpression in muscles (physical
training) can successfully prevent the occurrence of hy-
perglycaemia in these experimental conditions.
The process of increasing body mass by overnutri-
tion is regularly accompanied by a decrease of periph-
eral cell sensitivity to insulin and, at the same time, by
cellular glucose transport efficiency. These phenome-
na can be reversed by body mass normalization [21].
Skeletal muscle function, muscle training,
and cellular glucose transport
A deficit of GLUT4 in the muscles of experimental ani-
mals induces moderate hyperglycaemia and diabetes
mellitus. Insufficient utilization of glucose in skeletal
muscles is accompanied by GLUT4 translocation disor-
ders such as docking or fusion of sacs containing glu-
cose transporters in the cellular membrane or T chan-
nels. It is measured as a change of specific activity of
glucotransporters expressed as the amount of glucose
transported per glucotransporter concentration per time
Table I. Clinical significance of studies on GLUT4 activity [1–3]
Tabela I. Kliniczne znaczenie badań nad aktywnoscią GLUT4 [1–3]
Metabolic state — clinical syndrome Adipocytes Myocytes
GLUT4 transport protein GLUT4 transport protein
Obesity ØØ ØÆ
Diabetes mellitus type 2 ØØ ØØ ØØÆ
Diabetes mellitus type 1 Ø– ØÆ
Physical exercise ≠≠
Metabolic syndrome Insulin resistance related to a significant decrease of cellular glucose transport
Pregnancy
Liver cirrhosis
Hyperthyroidism
Turner Syndrome
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unit. It is suggested that the cause of these disorders is
abnormal insulin signal transduction inside the cell,
which primarily is related to improper activation of
phosphatidylinositol 3-kinase. It is often, at least partial-
ly, the result of decreased expression of the p85 mole-
cule responsible for the functional regulation of this ki-
nase. Insulin-stimulated phosphatidylinositol 3-kinase
function is impaired in insulin-resistant skeletal muscles.
This has been found in experimental studies on animal
models (rats with inherited obesity and hyperglycaemia
coexisting with hyperinsulinaemia) and in obese patients
with type 2 diabetes mellitus. Another cause of these ab-
normalities can be the storage of GLUT4 molecules in
insulin-unresponsive compartments.
New research techniques like nuclear magnetic res-
onance spectroscopy have enriched the knowledge con-
cerning the biochemical basis of molecular defects in
the metabolism of skeletal muscles existing in type 2
diabetes mellitus. For example, it was shown with these
methods that insulin resistance is often associated with
a decrease of insulin-related glycogen biosynthesis in
the skeletal muscle. This phenomenon is related to the
impairment of the activity of GLUT4 and, respectively,
cellular glucose transport (Fig. 2, Table II) [20, 21].
In the muscle and also in the liver, resistance to insulin
can be caused by the inhibition of the phosphorylation of
the insulin action signals by the metabolites of the lipid
metabolism, as, for example, diacylglycerol (DAG) and acyl
derivatives of fatty acids. It is clearly due to the inhibition
by fat of the function of IRS proteins. This subsequently
results in a decrease of PI -3K and cellular glucose trans-
port. Disturbances of this kind are observed particularly
in humans and in mice with lipodystrophy. In obesity,
the decrease of adipose tissue mass reduces the accumu-
lation of lipid metabolites in the myocytes and hepato-
cytes. At the same time, an increase of the sensitivity to
insulin is observed. It takes place even without changing
the concentration of the circulation in the blood of cytok-
ines like interleukin 6, resistin, or leptin (Fig. 3).
The increased cellular accumulation of the lipid
metabolites in persons without obesity and insulin re-
sistance may be related to the genetic regulation of mi-
tochondrial activities [1–3].
Many observations were made on the direct relation-
ship between the insulin action and the functional efficien-
cy of cellular glucose transport and whole body glucose
homeostasis [3, 5]. The expression of GLUT4 in adipocytes
of persons with type 2 diabetes mellitus is often signifi-
Figure 1. The influence of insulin actions on intracellular metabolic processes. The biochemical reactions and physiological effects are
successively harmonized and integrated [12]
Rycina 1. Wpływ aktywności insuliny na wewnątrzkomórkowe procesy metaboliczne. Reakcje biochemiczne i skutki fizjologiczne są
skutecznie zharmonizowane i zintegrowane
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cantly diminished [4–6]. At the same time, the level of
GLUT4 in skeletal muscle may be normal. Insulin resistance
in the striated muscle, therefore, may be related not only to
the amount of GLUT4 but also to the disturbances in its
translocation. The abnormalities may exist in the action of
the mediator molecules signalling the insulin action on the
translocation of GLUT4, which causes the absence of GLUT4
on the surface of cells. It was stated that the concentration
of GLUT4 is increased in exercised muscle.
Holten et al. studied the influence of physical ac-
tivity on insulin-mediated glucose uptake by GLUT4
and insulin signalling in the skeletal muscle of per-
sons with type 2 diabetes mellitus. Aerobic training
increased sensitivity to insulin in such patients [19].
In our own studies, the peripheral blood lympho-
cytes, as was established in the group of non-treated
patients with type 2 diabetes mellitus, had increased
expression of GLUT4.
Figure 2. Insulin signalling pathways. The signal of insulin association with the receptor stimulates insulin regulatory actions at the
beginning by its interaction with insulin receptor substrate (IRS) proteins. Phosphorylation of IRS proteins results in a number of
downstream effects. IRS-1 and IRS-2 have different functions. While IRS-1 has a predominant role in cell growth and insulin action in
muscle and adipose tissue, the effects of IRS-2 influence the b-cell and liver, and also brain growth, reproduction and food intake
Rycina 2. Szlaki przekazu sygnału dla insuliny. Sygnał połączenia insuliny z receptorem stymuluje aktywność regulatorową insuliny
początkowo przez oddziaływanie z białkami — substratem receptora insulinowego (IRS). Fosforylacja białek IRS powoduje liczne efekty;
IRS-1 i IRS-2 charakteryzują odmienne funkcje, podczas gdy IRS-1 odgrywa głównię rolę w pobudzaniu wzrostu komórkowego
i oddziaływaniu insuliny w mięśniach i tkance tłuszczowej, IRS-2 działa w komórkach b i wątrobie, a także wpływa na wzrost mózgu,
reprodukcję i przyjmowania pożywienia
Table II. Striated muscle and adipose tissue GLUT4 action in diabetes mellitus type 2 and obesity in human
Tabela II. Działanie GLUT4 w mięśniach poprzecznie prążkowanych i tkance tłuszczowej u chorych na cukrzycę typu 2
i osób otyłych
• The level of expression of GLUT4 in striated muscle in persons with diabetes mellitus type 1, 2 and with obesity is not significantly
changed. However, cellular glucose transport is diminished. It could be caused by disturbances in the function of the molecules
translocating GLUT4 to the cell membrane
• The muscle cellular glucose transport is significantly augmented by muscular work. Obesity significantly decreases the expression
of GLUT4 in adipocytes. This disturbance is much more visible in persons with obesity and diabetes mellitus type 2. A similar
perturbation was noted in women with gestational diabetes mellitus
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Drugs which influence the activity of cellular glucose
transport are mainly:
— insulin,
— sulphonylurea derivatives,
— metformin,
— thiazolidinediones,
— incretins,
— inhibitors of angiotensin-converting enzyme
— inhibitors of renal sodium glucose transport.
Insulin therapy
Insulin action primarily consists of three parallel path-
ways: 1) increase in cellular glucose transport; 2) stimu-
lation of glucose utilization; and 3) enhancement of pro-
liferative and antiapoptotic processes.
The state of knowledge of insulin influence on cel-
lular glucose transport has been presented abundantly
in literature [22–24].
Beta-cytotropic sulphonylurea derivatives
and cellular glucose transport
Hypoglycaemic sulphonylureas exert an influence on
cellular glucose transport [25–27]. In our studies, CGT
was studied before and after gliclazide therapy in
a group of type 2 diabetic patients who had previously
not received any pharmacotherapy and, comparative-
ly, in a group of healthy (control) subjects [2]. The study
can be summarized as presented below [28].
Background and aims
Impairment of CGT is involved in the pathogenesis of
diabetic hyperglycaemia and may therefore be regard-
ed as a target for the action of antidiabetic drugs. Stud-
ies devoted to this process may create new pharmaco-
therapeutic possibilities and interpretations. In order to
explore this hypothesis, CGT was studied before and
after gliclazide therapy in a group of type 2 diabetic
patients who had previously not received any phar-
macotherapy, and in a group of healthy subjects.
Material and methods
The CGT of peripheral blood lymphocytes (PBLs) was as-
sessed by timed incubation of cells with 2-[3H(G)] glucose
in basal conditions, and after the addition of gliclazide (in
substantia) or gliclazide plus insulin. Incubation tests were
performed at baseline in 28 newly diagnosed type 2 dia-
betics and 20 control subjects; in the diabetic patients, the
tests were repeated after three months of therapy with
gliclazide. PBLs were separated from whole blood by Fi-
coll-Isopaque gradient centrifugation. Incubation times
were 15, 30, and 60 minutes. The scintillation of PBL lysate
was measured with the Wallac 1450 MicroBeta counter.
Results
Treatment with gliclazide resulted in a statistically sig-
nificant reduction in fasting plasma glucose of
1.77 mmol/L (p < 0.001) and in HbAlc of 0.69% (p < 0.001).
The magnitude of CGT in PBLs (pg/300 000 cells) in
Figure 3. Structure of the human insulin receptor with several known point mutations [5–8]
Rycina 3. Budowa ludzkiego receptora insulinowego z kilkoma znanymi mutacjami punktowymi [5–8]
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healthy subjects and in type 2 diabetics before and af-
ter 12-week therapy with gliclazide (mean dose at the
end of the study, 39.6 mg) is presented in the table. In
all samples of PBLs, a significant increase was found in
CGT as a result of treatment with gliclazide (Table III).
All p values < 0.001.
Interpretation
When studied in the PBL model, CGT was found to be sig-
nificantly decreased in type 2 diabetes mellitus. It was par-
tially and significantly increased by the addition of gliclazide
to the incubation probe, and it was further increased by the
addition of insulin to gliclazide. The influence of gliclazide
on the CGT process constitutes a pleiotropic action of this
drug and underlines the importance of CGT as a target of
pharmacotherapy in type 2 diabetes mellitus.
Hypoglycaemic therapy also induced significant
changes in GLUT4 expression, as observed in our study
in peripheral blood lymphocytes [28] (Fig. 4).
Metformin
This biguanide normalizes the impairment of GLUT4
translocation in adipocytes as examined in vitro. Ad-
ministration of metformin to fa/fa Zucker rats increases
cellular glucose transport. GLUT4 and GLUT l translo-
cation to cellular membranes, and the transporter mol-
ecule activity.
In experimental conditions, administration of met-
formin increases the glucose transport without a change
in the level of GLUT4 in rat muscles. This effect of met-
formin is ascribed to the influence of metformin on
GLUT1.
In humans, metformin intensifies glucose absorp-
tion by striated muscle cells and increases cellular glu-
cose utilization in type 2 diabetes mellitus, which is as-
sociated with a decrease in insulin resistance. Many
studies suggest that the effect of metformin is the result
of AMP kinase activation. It is connected with the phos-
phorylation of threonine in position 172 of the alpha sub-
unit of the AMP kinase. It seems that metformin does not
influence insulin signalling by the PI 3-kinase pathway.
Galuska et al. examined the effect of metformin on
insulin action regulating cellular glucose transport in
isolated, striated muscle specimens obtained from pa-
tients with type 2 diabetes mellitus [29]. Metformin low-
ered hyperglycaemia by increasing tissue sensitivity to
insulin and glucose utilization, particularly in the stri-
ated muscle. It was shown that the transport of the glu-
cose analog 3-0-methyloglucose, as determined in the
biopsy muscle specimens, from the persons with type 2
Table III. Cellular glucose transport (CGT) in pg of glucose per 300,000 of lymphocytes from the peripheral blood (PBL) of type
2 diabetic patients: a — incubation medium only, b — gliclazide added to the incubation medium and c — gliclazide and
insulin (2 µj/mL) added to the incubation medium. CGT before therapy was significantly decreased, after 12 weeks of effective
therapy with diet, and gliclazide was significantly higher (authors’ own experiments)
Tabela III. Dokomórkowy transport glukozy (CGT) w pg na 300 000 limfocytów krwi obwodowej (PBL) chorych na cukrzycę
typu 2: a — tylko medium, b — medium z dodatkiem gliklazydu, c — medium z dodatkiem gliklazydu i insulin (2 µj/ml). CGT
przed terapią był istotnie obniżony, po 12 tygodniach leczenia dietą i gliklazydem zaobserwowano jego istotne zwiększenie
(badanie własne autorów)
Incubation model Incubation CGT intensity glucose transport
time (min)  in pg (300 000 lymphocytes)
Control subjects CGT–PBL CGT–PBL
Type 2 diabetic persons Type 2 diabetic persons after
before therapy 12 weeks of therapy with
Mean SD p Mean SD p Mean SD p
Lymphocytes, no 15 123.1 25.7 106.4 25.3 162.4 34.6
drugs added — a 30 228.7 58.8 179.4 32.3 308.1 57.5
60 442.8 137.8 263.1 47.8 543.6 62.1
Lymphocytes, gliclazide 15 203.6 49.1 < 0.001* 113.5 25.8 0.118* 210.3 36.7 < 0.001*
in substantia added — b 30 417.1 107.1 < 0.001* 199.0 36.3 < 0.001* 412.0 97.3 < 0.001*
60 664.1 186.8 < 0.001* 316.2 57.8 < 0.001* 727.2 147.5 < 0.001*
Lymphocytes, gliclazide 15 308.8 87.2 < 0.001** 186.4 28.4 < 0.001** 349.3 54.5 < 0.001*
in substantia and insulin 30 647.7 181.5 < 0.001** 293.3 56.7 < 0.001** 689.6 145.2 < 0.001*
added — c 60 666.7 186.4 0.469** 306.0 57.1  < 0.001** 709.7 150.0 < 0.001*
* v. sample 1
** v. sample 2
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diabetes mellitus was not changed by the metformin in
the concentration 0.01–0.1 mmol/L. For the increase of
the 3-0-methyloglucose transport in some of the exam-
ined persons, a metformin concentration of 0.1 mmol/L
was required. This concentration is higher than that
routinely used in clinical therapy with metformin.
However, in other studies it was found that metform-
in in a concentration of 0.06 mmol/L increases the process
of GLUT1 and GLUT4 translocation from the cytoplasm
to the cellular membrane of adipocytes. Such effects are
dose-dependent. In conclusion, it can be stated that the
action of metformin on glucose transport may have dif-
ferent mechanisms. Besides the effect on cellular glucose
transport, metformin may reduce insulin resistance in
many other ways; for example, by the increase of the ac-
tivity of the hexokinase and of the synthase of glycogen,
the efficiency of glucose oxidation and glycolysis.
A typical example of the influence
of metformin on the GLUT4 expression
in patients with type 2 diabetes mellitus
was observed in our own studies
Clinical observation — case description — metformin
therapy and GLUT4 expression in type 2 diabetes
mellitus. Male, 50 years of age, administration clerk.
Clinical data: diabetes mellitus type 2, no clinical symp-
toms of metabolic decompensation, BMI — 35.3 kg/m2,
BP — 150/100 mm Hg, HbA1c — 9.1%, glycaemia profile:
124––242 mg/dL, C-peptide, fasting — 2.86 ng/ml, choles-
terol total — 262 mg/dL, LDL-cholesterol — 144 mg/dL,
HDL--cholesterol — 46 mg/dL, triglycerides — 164 mg/dL.
Therapy: diet 1,500 kcal/244, metformin — 3 × 500 mg,
simvastatin — 20 mg, perindopril — 5 mg.
Observations of the effects of therapy are present-
ed in table 4. Metformin improved sensitivity to insulin
(HOMA) and at the same time decreased GLUT4 ex-
pression (Table IV).
Thiazolidinediones
These medicines stimulate the activity of peroxisome
proliferator-activated receptors a (PPAR-a), and in-
crease the cellular absorption and utilization of glucose
in patients with insulin resistance [30].
Administration of thiazolidinediones in insulin-re-
sistant rats normalizes the GLUT4 translocation in their
adipocytes. It has a similar influence on insulin resis-
tance caused by administration of TNF-a. With the use
of NMR, it has been shown that thiazolidinediones im-
prove the cellular glucose transport in type 2 diabetes
mellitus with insulin resistance. In such patients, thiaz-
olidinediones intensified the stimulation of the PI 3-ki-
nase by insulin and the activity of Akt by their positive
effect on glucose transport both in muscles and in adi-
pocytes. They increase GLUT4 translocation in cells. In
muscles, this effect is only slight.
Figure 4. Glucose transport stimulation by insulin. Molecular mechanisms of insulin-stimulated transport.The insulin-dependent
glucose transporter 4 (GLUT4) is translocated by a phosphatidylinositol3-kinase (PI-3K) - dependent pathway including PKB/AKT and
PKC stimulation downstream of PI-3K. PDK — phosphatidylinositol (3, 4, 5) — phosphate-dependent kinase; IRS, insulin receptor
substrate.
Rycina 4. Stymulacja transportu glukozy przez insulinę. Mechanizmy komórkowe transportu stymulowanego przez insulinę.
Insulinozależny transporter glukozy 4 (GLUT4) zostaje przemieszczony przez szlaki przekazu zależne od PI-3K (kinazy
fosfatydyloinozytolu 3), w tym stymulację PKB/AKT i PCK przez PI-3K. PDK — fosfatydyloinozytolo (3, 4, 5)-fosforo-zależna kinaza;
IRS — substrat receptora insuliny
(Häring H.U.: Exp Clin Endocrinol Diabetes 107 (suppl 2); s17–s23, 1999)
Insulin
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Table IV. Case of diabetes mellitus type 2 (male, 56 years of age, BMI — 31 kg/m2) — comparison of glycaemia, insulinaemia,
HOMA, and GLUT4 expression in peripheral blood lymphocytes before and after metformin therapy (see also the text)
Tabela IV. Chory na cukrzycę typu 2 (mężczyzna, 56 lat, BMI — 31 kg/m2) — porównanie wartości glikemii, insulinemii,
HOMA i ekspresji GLUT4 w limfocytach krwi obwodowej przed i po terapii metforminą (patrz tekst)
Glycaemia [mg/dL] Insulin in peripheral Therapy — 3 months Glycaemia [mg/dL] Insulin in peripheral
blood [mj/mL]   of metformin  blood [mj/mL]
3 × 500 mg
124 Fasting 28.0 98 Fasting 13.7
248 — 1 h After meal (breakfast) 96.2 162 After meal (breakfast) 58.2
210 — 2 h 110.5 139 46.1
182 — 3 h 82.4 100 32.2
HOMA 4.5 HOMA 3.0
GLUT4 expression GLUT4 expression
in lymphocytes  in lymphocytes
16.2% 2.8%
Incretin-mimetics and incretin-enhancers
The mucous membrane of the digestive tract, after com-
ing into contact with products of food digestion, secretes
about 30 hormones. A special place among these hor-
mones is held by glucagon-like peptide l (GLP-1) and
glycaemia-dependent gastric inhibitory polypeptide
(GIP). Receptors of these peptides are located in b-cells
and in the lungs, brain, liver, skeletal muscles, and kid-
neys. They have a stimulating influence, especially on
postprandial biosynthesis and insulin secretion (about
50% of this reaction) [15]. In this way, they decrease
hyperglycaemia in type 2 diabetes mellitus. Moreover,
they exhibit a lot of other systemic effects such as a de-
crease of glucagon secretion, an increase of peripheral
cells glucose utilization, a decrease of the gluconeogen-
esis and glucose production in the liver, stimulation of
satiety, and an increase of stomach contractions. There-
fore, GLP-l also regulates glycaemia, independently of
insulin. Such an influence by GLP l is connected with
its action on cellular glucose transport. It has been ex-
perimentally proven that GLP-l stimulates the expres-
sion of specific beta-cell genes. This stimulation involves
not only the insulin gene, but also the GLUT l glu-
cotransporter gene and the glucose phosphorylating
enzyme gene of hexokinase-1. GLP-1 regulates the tran-
scription of the GLUT l gene and hexokinase-l gene, as
well as stabilizing insulin mRNA.
In studies on aging Wistar rats, it has been shown
that GLP-l increases their glycaemia dependently on
insulin secretion and normalizes the impairment of glu-
cose tolerance related to age. It was connected with an
increase in levels of mRNA for insulin, GLUT 2 mole-
cules, and glucokinase of beta cells. The use of the GLP-
l agonists gave similar results.
One of the important mechanisms increasing the
concentration and action of GLP-l and GIP is inhibition
of the activity of the enzyme that decomposes these
hormones — dipeptidyl peptidase-4 (DPP-4). There are
other substances of this kind which have also been of-
fered in the form of incretin enhancers.
DPP-4 inhibitors have a positive influence on the
size of the pancreatic islet mass and on the biological
vitality of b cells — their morphology, their lifespan,
and their resistance to apoptosis. They can also inhibit
the decomposition of other biologically important pep-
tides (e.g. aprotinin, bradykinin, endomorphin, GLP 2,
NPY, prolactin, growth hormone, P substance). DPP-4
inhibitors decrease hyperglycaemia in individuals with
type 2 diabetes by lowering GLP l and GIP catabolism
and, therefore, increasing their blood concentration and
action. It seems that the DPP-4 inhibitors action (sitaglip-
tin, vildagliptin), decreasing insulin resistance, is com-
bined with increased activity of glucose transporters [15].
Angiotensin inhibitors
Angiotensin decreases the influence of insulin on cellu-
lar glucose transport, especially in the heart. ACE in-
hibitors enhance the influence of insulin on GLUT4
translocation, probably by intensifying the action of
bradykinin and NO.
The antagonists of angiotensin II receptors have similar
effects (sartanes). These effects occur only in experimental
animals with insulin resistance, but have not been proven
in experimental animals with normal insulin sensitivity.
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Inhibitors of renal sodium/glucose transport
Studies on the function of sodium–glucose cotransport-
ers from the SGLT family became the basis for propos-
ing their inhibitors as experimental drugs [32]. An exam-
ple of such an SLGT inhibitor is dapagliflozin, a selective
SLGT 2 inhibitor studied as a potential drug for decreas-
ing glycaemia (particularly fasting) by the increase of re-
nal glucosuria (EASD An. Meeting, 2007, Amsterdam,
Komoroski B. J. et al.). This increase is proportional to
the hyperglycaemia and results in its lowering.
Conclusions
Studies of cellular glucose transport create new cogni-
tive ideas in the area of the pathogenesis of many dis-
eases associated with insulin resistance. They have the
potential of practical innovations.
In diabetes mellitus, hyperglycaemia in the extra-
cellular space is associated with a deficit and a signifi-
cant decrease of glucose utilization within the periph-
eral cells. These basic, pathogenetic phenomena occur
as the result of a decrease of the regulatory action of
insulin on the cells. The cause of such disturbances could
be the insulin resistance and relative insulin deficit, or
both of these pathophysiological conditions occurring
simultaneously.
Knowledge of the structure and the mechanisms of
glucose transporters action connected with insulin re-
sistance has significantly enriched the understanding
of the molecular pathogenesis of diabetes mellitus. It is
already known that type 2 diabetes mellitus could be
related to, among other factors, improper structure and/
/or function of the GLUT4 transporter. The molecular,
pathogenetic possibility involves damage to molecules
of the insulin signalling pathway through which insulin
stimulates the exocytosis of GLUT4. Such damage can
also involve the insulin receptor or molecules transmit-
ting signals from the receptor to the sacs which contain
GLUT4 and serve as the translocating GLUT4 vesicles.
The insulin regulatory action on glucose metabolism
in peripheral cells begins with an intensification of cel-
lular glucose transport. In diabetes mellitus, it is im-
paired. Cellular glucose transport abnormalities in the
cellular glucose transport system are typically associat-
ed with insulin resistance.
Therefore, the structural and functional determina-
tion of glucose transport in practice may offer impor-
tant clinical advantages for more precise diagnosis of
metabolic pathology, classification of diabetes mellitus,
and for inventing new therapies. Studies in this area
are very active.
Pathologies related to cellular glucose transport dis-
orders and insulin resistance also involve the pathogen-
esis of tumours, atherosclerosis, and many other diseas-
es influenced by changes in this basic function of cells.
Studies of cellular glucose transport also provide
new information about the biological mechanisms of
the action of many hormones, regulating factors, and
pharmacological agents in the area of insulin resistance.
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